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Learning Objectives
Identify patients with levetiracetam induced 
pancytopenia. 
Describe management of pancytopenia induced by 
levetiracetam. 
DiscussionLaboratory Studies
❖ Levetiracetam (Keppra) is a pyrrolidone derivative 
and acts as an anti-epileptic medication by 
modulating neurotransmitter release.  
❖ Levetiracetam was approved by FDA for partial 
seizure, myoclonic seizure, and generalized tonic-
clonic seizure. It is used off-label as seizure 
prophylaxis.  
❖ This medication is associated with a few side effects 
that include behavioral changes, headache, 
drowsiness, and weakness.  
❖ Hematologic adverse effects are rarely caused by 
this therapy. These effects include anemia, 
thrombocytopenia, and leukopenia.  
❖ Pancytopenia is a very rare adverse effect caused by 
levetiracetam. There are fewer than four case reports 
in the medical literature discussing the association 
between levetiracetam and pancytopenia.  
❖ The pathogenesis behind this relationship is unclear. 
❖ Our patient developed pancytopenia induced by 
levetiracetam which resolved after we discontinued 
this medication.  
❖ Her hemolysis profile and blood smear did not reveal 
any signs of hemolysis. Therefore, we hypothesize 
that levetiracetam induced pancytopenia by causing 
bone marrow suppression.
Fig 1:Graph depicting relationship between white blood cell count and 
number of days post-operatively (POD). Levetiracetam was started on 
post-operative day 0 and was discontinued on post-operative day 10. 
Development of leukopenia was witnessed with start of levetiracetam and 




 A 79-year-old female with a medical history of hypertension, type 
II diabetes, and CVA who presented with MRI brain showing a 
right temporoparietal mass.  
Hospital Course: 
❖ Patient was started on dexamethasone prior to surgery due 
to the extensive amount of vasogenic edema.  
❖ She underwent a temporal craniotomy with resection of the 
mass.  
❖ Levetiracetam was started off-label as seizure prophylaxis.  
❖ Postoperatively, her blood count remained stable.  
❖ She was on levetiracetam, dexamethasone, pantoprazole,          
and enoxaparin as prophylaxis.  
❖ She was noted to have an episode of melena and anemia 
on the fifth day postoperatively. 
❖ Two units of packed red blood cell were transfused with an 
appropriate response.  
❖ No acute gastroenterological intervention was deemed 
necessary at that time. 
❖ The patient was also noted to develop thrombocytopenia 
and leukopenia.  
❖ Thrombotic thrombocytopenic purpura, disseminated 
intravascular coagulation, and heparin-induced 
thrombocytopenia were ruled out.  
❖ Pantoprazole and enoxaparin were discontinued without 
any improvement in cell counts.  
❖ The patient received a total of five units of platelets due to 
a platelet count of less than 100,000.  
❖ Levetiracetam was changed to lacosamide on day ten post-
operative, and dexamethasone was continued without 
change.  
❖ Within 24 hours of discontinuing levetiracetam, the platelet 
counts improved and continued to trend upward.  
❖ A noticeable increase in white blood cells and hemoglobin 
were seen five days after that.
Conclusion
❖ Clinicians should be aware that levetiracetam 
induces severe pancytopenia.  
❖ Clinicians should consider changing levetiracetam to 
other agents in patients who develop pancytopenia 
with negative hemolysis profile.  
❖ Further studies should be conducted to explain how 
levetiracetam induces bone marrow suppression and 
to find a diagnostic test for diagnosis.  
❖ This case will serve to spread awareness of a rare 
cause of pancytopenia and to hypothesize how this 
medication causes pancytopenia.
Fig 3: Graphs depicting relationship between red blood cell count  and 
hemoglobin and number of days post-operatively (POD). Levetiracetam 
was started on post-operative day 0 and was discontinued on post-
operative day 10. Patient experienced an acute bleed requiring 
transfusion of 2 units of RBC on POD 5, followed by a steady decline in 
Hbg and RBC. improvement in anemia was observed with discontinuation 
of the medication.
Fig 4: Blood smear showing lack of schistocytes, and immature cell 
lines. Findings on blood smear correlate with absence of disseminated 
intravascular coagulation and thrombotic thrombocytopenic purpura, and 
are suggestive of bone marrow suppression.
Fig 2: Graph depicting relationship between platelet count and number 
of days post-operatively (POD). Levetiracetam was started on post-
operative day 0 and  was discontinued on post-operative day 10. 
Development of thrombocytopenia was witnessed with start of 
levetiracetam and improvement in thrombocytopenia was observed with 
discontinuation of the medication. Patient was transfused 5 units of 
platelet on POD 8 and POD 9.
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